The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 06, 2023
Filed:
Apr. 27, 2020
Applicant:
Auspex Pharmaceuticals, Inc., Parsippany, NJ (US);
Inventors:
Andreas Sommer, Carlsbad, CA (US);
Chengzhi Zhang, San Diego, CA (US);
John Carter, Vista, CA (US);
John Charles Arthur, Vista, CA (US);
Margaret Bradbury, Vista, CA (US);
Thomas George Gant, Carlsbad, CA (US);
Manouchehr Shahbaz, San Diego, CA (US);
Assignee:
Auspex Pharmaceuticals, Inc., Parsippany, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 47/38 (2006.01); A61P 25/14 (2006.01); A61K 31/473 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61K 31/4745 (2006.01); A61K 45/06 (2006.01); C07D 455/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/473 (2013.01); A61K 9/0053 (2013.01); A61K 9/0065 (2013.01); A61K 9/1676 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2072 (2013.01); A61K 9/2077 (2013.01); A61K 9/2095 (2013.01); A61K 9/28 (2013.01); A61K 9/284 (2013.01); A61K 9/288 (2013.01); A61K 9/2846 (2013.01); A61K 9/2866 (2013.01); A61K 9/4808 (2013.01); A61K 9/5047 (2013.01); A61K 9/5073 (2013.01); A61K 9/5078 (2013.01); A61K 9/5084 (2013.01); A61K 31/4745 (2013.01); A61K 45/06 (2013.01); C07D 455/06 (2013.01); C07B 2200/05 (2013.01);
Abstract
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.